CG Oncology (CG Oncology) Total Long-Term Liabilities : $0.18 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. CG Oncology's Total Long-Term Liabilities for the quarter that ended in Mar. 2024 was $0.18 Mil.

CG Oncology Total Long-Term Liabilities Historical Data

The historical data trend for CG Oncology's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Total Long-Term Liabilities Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Total Long-Term Liabilities

95.34

7.14

0.26

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Total Long-Term Liabilities	Get a 7-Day Free Trial			7.14	-	308.21	0.26	0.18

CG Oncology Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

CG Oncology Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of CG Oncology's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Total Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024